Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 10/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18932909 | 0.88 | L3MBTL1 (0.63) | RIPK1L3MBTL1GAANPC1RAB9A | |
| SCHEMBL18932911 | 0.82 | L3MBTL1 (0.56) | RIPK1L3MBTL1GAANPC1RAB9A | |
| SCHEMBL18889270 | 0.80 | L3MBTL1 (0.69) | RIPK1L3MBTL1GAANPC1RAB9A | |
| SCHEMBL6231088 | 0.80 | L3MBTL1 (0.69) | RIPK1L3MBTL1GAANPC1RAB9A | |
| SCHEMBL18889279 | 0.78 | RIPK1 (0.69) | RIPK1L3MBTL1NPC1RAB9AHPGD | |
| SCHEMBL18889266 | 0.78 | RIPK1 (1.00) | RIPK1L3MBTL1NPC1RAB9AHPGD | |
| SCHEMBL6233482 | 0.77 | GAA (1.00) | L3MBTL1GAANPC1RAB9AHPGD | |
| SCHEMBL18889299 | 0.76 | RIPK1 (0.73) | RIPK1L3MBTL1NPC1RAB9A | |
| SCHEMBL3499370 | 0.76 | BCL2L1 (0.53) | — | |
| SCHEMBL18889276 | 0.74 | RIPK1 (1.00) | RIPK1L3MBTL1NPC1RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3176163-B1 | NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | IAC IN NAT UNIV CHUNGNAM (KR) | 2019-04-17 | — | — | EP | claimed |
| EP-3176163-A1 | NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | The Industry & Academic Cooperation in Chungnam National University (IAC) (KR) | 2017-06-07 | — | — | EP | claimed |
| US-20170152268-A1 | NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | MOTHER'S PHARMACEUTICAL CO., LTD. (KR) | 2017-06-01 | — | — | US | claimed |
| EP-3176163-B1 | NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | IAC IN NAT UNIV CHUNGNAM (KR) | 2019-04-17 | — | — | EP | disclosed |
| EP-3176163-A1 | NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | The Industry & Academic Cooperation in Chungnam National University (IAC) (KR) | 2017-06-07 | — | — | EP | disclosed |
| EP-3176163-A1 | NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | The Industry & Academic Cooperation in Chungnam National University (IAC) (KR) | 2017-06-07 | — | — | EP | disclosed |
| US-20170152268-A1 | NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | MOTHER'S PHARMACEUTICAL CO., LTD. (KR) | 2017-06-01 | — | — | US | disclosed |
| US-20170152268-A1 | NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | MOTHER'S PHARMACEUTICAL CO., LTD. (KR) | 2017-06-01 | — | — | US | disclosed |
| US-20170152268-A1 | NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | MOTHER'S PHARMACEUTICAL CO., LTD. (KR) | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152268-A1 | NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885L3MBTL1 2632/4885GAA 2754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.